Qilu pharmaceutical ondansetron hydrochloride injection is approved to be listed in the United States
-
Last Update: 2014-10-13
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
FDA of the United States is currently recognized as the most stringent drug review in the world, in which the quality control, hardware facilities, staffing, production specifications and other requirements for sterile injection product manufacturers are more stringent At present, most of the drugs exported by China to the United States are APIs, and most of the preparations are ordinary solid preparations As early as 1994, Qilu pharmaceutical first imitated ondansetron hydrochloride injection in China This product is a "gold standard" drug used to prevent vomiting due to treatment, chemotherapy and other reasons Because of its advantages of good quality, outstanding safety, and significant clinical effect, Qilu pharmaceutical has been the first in the domestic market share since its listing The successful approval of ondansetron hydrochloride injection is another major breakthrough made by Qilu pharmaceutical in the export of pharmaceutical products to the U.S market after the export of a variety of preparations and many APIs to European Union, the United States, Australia and other countries and regions, marking that Qilu pharmaceutical's drug research and development, product production, and quality control capabilities have once again been highly recognized by the international market.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
